Offerings // Xeris Biopharma Holdings, Inc.

XERS offering history

Every offering-related filing in Xeris Biopharma Holdings, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 321 filings back to Jul 2, 2021.

Last executed offering

Jul 17, 2026

8-K — priced deal (shares or notes)

Last registration (announced)

Mar 6, 2025

S-3 — capacity, not a sale

Executed, last 12 months

424B pricings + 8-K 3.02 sales

Registered, last 12 months

S-1/S-3/F-series registrations

Date	Filing		What it means
Jul 17, 2026	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Jun 11, 2026	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
May 13, 2025	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Mar 6, 2025	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Sep 29, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Sep 27, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
May 11, 2022	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Feb 8, 2022	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Feb 7, 2022	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Feb 7, 2022	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Jan 28, 2022	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Jan 28, 2022	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Jan 3, 2022	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Jul 29, 2021	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Jul 29, 2021	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin

XERS offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full XERS workspace →

XERS offering FAQ

When did XERS last execute an offering?

Per SEC filings, Xeris Biopharma Holdings, Inc.'s most recent priced offering document is a 8-K filed 2026-07-17. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did XERS last announce or register an offering?

The most recent registration is a S-3 filed 2025-03-06. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.